Zynerba Pharma (ZYNE) Reports Q3 Loss of $0.63/Share

Zynerba Pharma (NASDAQ: ZYNE) reported Q3 EPS of ($0.63), versus ($0.67) reported last year.

Financial Outlook

The Company believes that the cash and cash equivalent position of $66.3 million as of September 30, 2017 is sufficient to develop five Phase 3-ready programs and initiate at least one pivotal program and fund operations and capital requirements into 2019

For earnings history and earnings-related data on Zynerba Pharma (ZYNE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c